Jaime Merchan, MD, discusses the efficacy results observed in the LITESPARK-013 trial of belzutifan in patients with advanced clear cell renal cell carcinoma.
Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...
The committee also recommended conditional approval of the drug for the treatment of adult patients with advanced clear cell ...
Phase 1 results support further evaluation of ALLO-316 in patients with CD70-positive clear cell renal cell carcinoma, according to researchers.
News Medical on MSN4d
New $1.4M grant supports innovative kidney cancer treatment strategyWeill Cornell Medicine has received a $1.4 million, four-year grant from the U.S. Department of Defense to investigate a new therapeutic approach for the most common form of kidney cancer.
Defective VHL protein is also present in most cases of advanced clear cell renal cell carcinoma (RCC), so a recommendation for belzutifan was issued to also cover this condition. The drug is indicated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback